

FAST FACTS

NRG CC008 - A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]


Eligibility Criteria

1. Individuals 35-50 years of age, inclusive.
2. Patients who are undergoing RRSO (for the BSO arm) and patients who have declined or elected to defer BSO after proper counselling to clearly explain the standard of care for BRCA1 mutation carriers and are undergoing salpingectomy (for the BLS arm with delayed oophorectomy arm). Concurrently planned hysterectomy with either arm is permitted.
3. At least one intact ovary and fallopian tube is in situ at the time of counseling and consent. Prior hysterectomy is allowed provided it did not include bilateral salpingectomy. Prior tubal ligation is allowed if one ovary and fallopian tube (with fimbria not removed) are present.
4. Positive CLIA-approved test results for pathogenic or likely pathogenic germline *BRCA1* mutation in the patient. Documentation of the result is required.
5. Patients may be premenopausal.
6. Transvaginal ultrasound (TVUS) and CA-125 within 180 days of registration.
7. The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.
8. Individuals who are currently pregnant or plan to become pregnant in the future through assisted reproductive technologies and who have received proper counseling are eligible. Individuals who are currently pregnant and plan bilateral salpingectomy at the time of a planned cesarean section are eligible. Patients must understand that they will not be able to become pregnant naturally in the future.

Ineligibility Criteria

1. Individuals with a history of any prior cancer who have received chemotherapy within the past 30 days, or radiotherapy to abdomen or pelvis at any prior time.
2. Prior history of ovarian cancer, including low malignant potential neoplasms (LMP), primary peritoneal carcinoma, or fallopian tube carcinoma.
3. Patients medically unfit for the planned surgical procedure.
4. Patients with abnormal screening tests (TVUS, CA-125) suspicious for occult or gross pelvic malignancy or neoplasm within the past 180 days.
 - a. An abnormal TVUS is defined as morphologic or structural variations suspicious for ovarian malignancy or complex cystic lesions (simple cysts <5cm in maximal diameter are not exclusionary).
 - b. An abnormal CA-125 is defined as a level >50U/ml in premenopausal individuals if they are not current users of oral contraceptives; an abnormal CA-125 is defined as a level >40U/ml for premenopausal individuals who are current users of oral contraceptives (Skates 2011). An abnormal CA-125 is defined as a level >35U/ml in postmenopausal individuals.

NRG-CC008
SCHEMA (26-MAY-2022)



BLS-bilaterally salpingectomy, BSO-bilateral salpingo-oophorectomy